Tenax Therapeutics Inc (FRA:YBO0)
€ 1.43 -0.090 (-5.92%) Market Cap: 56.04 Mil Enterprise Value: -44.91 Mil PE Ratio: 0 PB Ratio: 0.49 GF Score: 33/100

Tenax Therapeutics Inc To Discuss the Topline Level Results Transcript

Aug 10, 2026 / 12:00PM GMT
Operator

Good day and welcome to the Tenex Therapeutics Phase 3 Level Top-Line Results Conference Call.

All participants will be in a listen-only mode.

Should you need assistance, please signal a conference specialist by pressing the star key followed by 0.

After today's presentation, there will be an opportunity to ask questions.

To ask a question, you may press star then 1 on a touch-tone phone.

To withdraw your question, please press star then 2.

Please note, this event is being recorded.

I would now like to turn the conference over to Chris Giordano, President and Chief Executive Officer. Please go ahead.

Christopher Giordano
Tenax Therapeutics Inc - President, Chief Executive Officer, Director

Good morning, everyone.

Thank you, Betsy.

Thank you everyone for joining us. I'm Chris Giordano, President and Chief Executive Officer of Tenax Therapeutics.

This morning, we released top-line results from Level, our first phase three trial of oral levosimendin in patients with

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot